



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 80185

**Title:** Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 02567652

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** United Kingdom

**Manuscript submission date:** 2022-09-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-09-20 01:58

**Reviewer performed review:** 2022-09-21 14:22

**Review time:** 1 Day and 12 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous
	Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

### **SPECIFIC COMMENTS TO AUTHORS**

This study aims to present a summary and review the available published data to help us understand the emerging role of dual biologic therapy in inflammatory bowel disease. The authors explore the efficacy and safety of dual biologic therapy in IBD according to different types of studies such as RCT, case report, et al, but it lacks a systematic summary of dual biologic therapy. Therefore, the overall structure appears messy and lacks logic. Regarding the safety of dual biologic therapy, short- and long-term safety needs to be discussed.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 80185

**Title:** Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06080523

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Academic Research, Assistant Professor

**Reviewer's Country/Territory:** Brazil

**Author's Country/Territory:** United Kingdom

**Manuscript submission date:** 2022-09-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-09-20 13:46

**Reviewer performed review:** 2022-10-02 17:55

**Review time:** 12 Days and 4 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### **SPECIFIC COMMENTS TO AUTHORS**

The authors aimed to present a summary and review the available published data in this area to help us better understand the emerging role of dual biologic therapy in inflammatory bowel disease. It is a well written article. I would like to suggest some points to further improve the article. - I suggest that authors include the purpose of the article at the end of the introduction. - When the authors cite the randomized controlled trials of combination of biological therapy, the VEGA study - Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study. Gastroenterol Hepatol (N Y). 2022. Apr;18(4 Suppl 1):9-10. PMID: 35610992, was published in the abstract form. It is up to the authors to include this abstract in this article.